FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 428 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR A New Online Tool Predicts RFS and OS Probabilities in Patients... February 7, 2024 How to Prepare for Lung Cancer Treatment to Help With Recovery December 15, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Pralsetinib September 28, 2021 Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in... September 27, 2024 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma Aggressive Prostate Cancer Subtype More Common Than Expected Adding More Mushrooms to Your Diet May Decrease Your Risk of...
